Physician profile
Michael J Simon
NPI 1538185657
$52,275.66
in general payments reported to CMS, 2019-2025
55 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,016 · 2020: $3,859 · 2021: $5,657 · 2022: $3,837 · 2023: $4,472 · 2024: $13K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $13K · Travel and Lodging: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,452.00 |
| Food and Beverage | $13,300.97 |
| Travel and Lodging | $1,153.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $15,474.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $11,897.37 | 2019-2025 | |
| Novo Nordisk INC | $2,755.76 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $2,100.99 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,695.74 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Biohaven Pharmaceuticals, INC. | $1,343.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $1,210.95 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $1,169.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,147.58 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $1,077.67 | 2021-2025 | |
| Amgen INC. | $1,050.58 | 2019-2025 | Repatha, Otezla, Repatha |
| Corcept Therapeutics | $954.38 | 2023-2025 | Korlym |
| Merck Sharp & Dohme LLC | $858.05 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $836.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $779.31 | 2019-2025 | Jardiance, Cyltezo, Ofev |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.